Genomtec S.A. (WSE:GMT)

Market Cap	46.25M -54.2%
Revenue (ttm)	35.00K +218.2%
Net Income	-7.93M
EPS	n/a
Shares Out	15.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,491
Open	3.020
Previous Close	3.080
Day's Range	3.005 - 3.080
52-Week Range	3.000 - 6.870
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detectio...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Employees: 32
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GMT

Financial Performance

In 2025, Genomtec's revenue was 19,000, an increase of 1800.00% compared to the previous year's 1,000. Losses were -10.22 million, -8.80% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error